Bristol BuSpar Pediatric Labeling May Delay Second Round Of Generics
Executive Summary
The second round of generic approvals for Bristol's anti-anxiety drug BuSpar (buspirone) appears to be held up by Bristol's attempts to enforce exclusivity based on a change in labeling related to pediatric studies.
You may also be interested in...
J&J Ultram Titration Relabeling Should Not Block Generics, Apotex Argues
Apotex' citizen petition requesting approval of generic Ultram argues that Johnson & Johnson did not make labeling changes for safety or efficacy reasons
J&J Ultram Titration Relabeling Should Not Block Generics, Apotex Argues
Apotex' citizen petition requesting approval of generic Ultram argues that Johnson & Johnson did not make labeling changes for safety or efficacy reasons
Bristol Glucophage Managed Care Discounts Will Encourage Switches
Bristol-Myers Squibb is looking to its managed care contracting for Glucophage to increase growth in the newer once-daily and combination formulations of the antidiabetic.